Sotorasib is Used for treating adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received at least one prior systemic therapy. It was first introduced by Amgen Inc in its drug Lumakras on May 28, 2021.

Sotorasib Patents

Given below is the list of patents protecting Sotorasib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Lumakras	US10519146	KRAS G12C inhibitors and methods of using the same	May 21, 2038	Amgen Inc
Lumakras	US11236091	Solid state forms	May 20, 2040	Amgen Inc
Lumakras	US11426404	Dosing of KRAS inhibitor for treatment of cancers	Sep 15, 2040	Amgen Inc
Lumakras	US11827635	Solid state forms	May 20, 2040	Amgen Inc

Add above patents to watchlist

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳